Stockscreener 앱 받기
33.61
2.47%
0.81
시장 영업 전:
32.45
-1.16
-3.45%
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman - marketscreener.com
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman - GlobeNewswire Inc.
Soleno Lawsuit Puts DCCR Safety Disclosures And Growth Story Under Scrutiny - simplywall.st
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Soleno - GlobeNewswire
DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Soleno ... - Bluefield Daily Telegraph
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT - GlobeNewswire
Soleno Therapeutics Faces Class Action Lawsuit - National Today
Soleno Therapeutics stock hits 52-week low at 32.51 USD By Investing.com - Investing.com South Africa
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - GlobeNewswire Inc.
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hy - GuruFocus
Oppenheimer Lowers Soleno Therapeutics (NASDAQ:SLNO) Price Target to $80.00 - MarketBeat
Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says - marketscreener.com
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman – Company AnnouncementFT.com - Financial Times
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week LowHere's What Happened - MarketBeat
Soleno Therapeutics stock hits 52-week low at 32.51 USD - Investing.com
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky - PR Newswire
Oppenheimer Adjusts Price Target on Soleno Therapeutics to $80 From $110, Maintains Outperform Rating - marketscreener.com
Oppenheimer cuts Soleno Therapeutics stock price target on slower launch By Investing.com - Investing.com South Africa
Oppenheimer cuts Soleno Therapeutics stock price target on slower launch - Investing.com
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Soleno Therapeutics : February 2026 Corporate Presentation - marketscreener.com
Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Soleno Therapeutics, Inc. (SLNO) Class Action Lawsuit Seeks Recovery for Investors; May 5, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - The Globe and Mail
SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Cla - GuruFocus
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Holocene Advisors LP Trims Stake in Soleno Therapeutics, Inc. $SLNO - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages Soleno Therapeutics, - GlobeNewswire
Soleno Therapeutics, Inc. (SLNO) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Chronicle-Journal
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 – Company Announcement - Financial Times
Soleno Therapeutics, Inc. 8-K Filing Details, Company Information, and Amended Bylaws (March 16, 2026) - Minichart
Soleno Therapeutics Target of Unusually Large Options Trading (NASDAQ:SLNO) - MarketBeat
Granahan Investment Management Boosts Stake in Soleno Therapeutics - National Today
Soleno Therapeutics amends bylaws to update governance and legal provisions - Investing.com
Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class ActionRGRD Law - Financial Times
Soleno Therapeutics (SLNO) Board adopts amended and restated bylaws - Stock Titan
Soleno Therapeutics Inc (NASDAQ:SLNO) Emerges as a Potential Fair-Value Opportunity - ChartMill
301,000 Shares in Soleno Therapeutics, Inc. $SLNO Purchased by Kingdon Capital Management L.L.C. - MarketBeat
Granahan Investment Management LLC Has $7.39 Million Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Farallon Capital Management LLC Raises Stock Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno (NASDAQ:SLNO) Gains Market Attention In Nasdaq Composite - Kalkine Media
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
2026-03-15 | SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:SLNO | Press Release - Stockhouse
Commodore Capital LP Raises Stock Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):